9.85
-0.05(-0.51%)
Currency In USD
| Previous Close | 9.9 |
| Open | 9.8 |
| Day High | 9.89 |
| Day Low | 9.4 |
| 52-Week High | 13.85 |
| 52-Week Low | 2.89 |
| Volume | 757,960 |
| Average Volume | 1.2M |
| Market Cap | 597.67M |
| PE | -12.31 |
| EPS | -0.8 |
| Moving Average 50 Days | 10.2 |
| Moving Average 200 Days | 6.18 |
| Change | -0.05 |
If you invested $1000 in CorMedix Inc. (CRMD) 10 years ago, it would be worth $1,427.54 as of December 04, 2024 at a share price of $9.85. Whereas If you bought $1000 worth of CorMedix Inc. (CRMD) shares 5 years ago, it would be worth $1,625.41 as of December 04, 2024 at a share price of $9.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products
GlobeNewswire Inc.
Nov 26, 2024 1:30 PM GMT
BERKELEY HEIGHTS, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today highlights key po
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium
GlobeNewswire Inc.
Nov 04, 2024 1:30 PM GMT
BERKELEY HEIGHTS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that ma
CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update
GlobeNewswire Inc.
Oct 30, 2024 11:30 AM GMT
‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- CorMedix